Education
About Us
Working with TipRanks
Follow Us
Royalty Pharma PLC (RPRX)
NASDAQ:RPRX
RPRX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$24.05 - $38.00
Previous CloseN/A
Volume726.99K
Average Volume (3M)2.86M
Market Cap
$21.29B
Enterprise Value$30.79B
Total Cash (Recent Filing)$645.11M
Total Debt (Recent Filing)$8.02B
Price to Earnings (P/E)15.9
Beta0.30
Next Earnings
Nov 05, 2025EPS Estimate
1.05Last Dividend Ex-Date
Aug 15, 2025Dividend Yield2.38%
Share Statistics
EPS (TTM)1.14
Shares Outstanding432,293,060
10 Day Avg. Volume3,377,146
30 Day Avg. Volume2,860,931
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.45
Enterprise Value/Revenue13.35
Enterprise Value/Gross Profit17.85
Enterprise Value/Ebitda16.27
Forecast
1Y Price Target
$43.33Price Target Upside18.71% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Bulls Say, Bears Say
Bulls Say
Oncology Asset UpsideThe announced royalty financing deal with Revolution Medicines allows Royalty Pharma to participate in the upside of the target asset daraxonrasib for oncology.
Regulatory AchievementsFDA has granted Breakthrough Therapy Designation to daraxonrasib for previously treated metastatic PDAC in patients with KRAS G12 mutations.
Strategic DirectionThe transaction sets Royalty Pharma on track to meet or exceed its 5-year capital deployment target, demonstrating confidence in their strategic direction.
Bears Say
Market CompetitionTremfya should fight Skyrizi to a draw in ulcerative colitis, and RPRX garners a tiered mid-single digit royalty on Tremfya through 2031-32.
Pipeline ChallengesThe company can adapt to potential changes in the regulatory environment due to the absence of an internal pipeline.
Royalty Pharma News
RPRX FAQ
What was Royalty Pharma PLC’s price range in the past 12 months?
Royalty Pharma PLC lowest stock price was $24.05 and its highest was $38.00 in the past 12 months.
What is Royalty Pharma PLC’s market cap?
Royalty Pharma PLC’s market cap is $21.29B.
When is Royalty Pharma PLC’s upcoming earnings report date?
Royalty Pharma PLC’s upcoming earnings report date is Nov 05, 2025 which is in 81 days.
How were Royalty Pharma PLC’s earnings last quarter?
Royalty Pharma PLC released its earnings results on Aug 06, 2025. The company reported $1.141 earnings per share for the quarter, beating the consensus estimate of $1.032 by $0.109.
Is Royalty Pharma PLC overvalued?
According to Wall Street analysts Royalty Pharma PLC’s price is currently Undervalued.
Does Royalty Pharma PLC pay dividends?
Royalty Pharma PLC pays a Quarterly dividend of $0.22 which represents an annual dividend yield of 2.38%. See more information on Royalty Pharma PLC dividends here
What is Royalty Pharma PLC’s EPS estimate?
Royalty Pharma PLC’s EPS estimate is 1.05.
How many shares outstanding does Royalty Pharma PLC have?
Royalty Pharma PLC has 432,293,060 shares outstanding.
What happened to Royalty Pharma PLC’s price movement after its last earnings report?
Royalty Pharma PLC reported an EPS of $1.141 in its last earnings report, beating expectations of $1.032. Following the earnings report the stock price went down -2.084%.
Which hedge fund is a major shareholder of Royalty Pharma PLC?
Currently, no hedge funds are holding shares in RPRX
Royalty Pharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$43.33 (18.71% Upside)
$43.33 (18.71% Upside)
Blogger Sentiment
Bullish
RPRX Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 2.6M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days >0.1%
Last 30 Days ▼ 3.0%
Last 30 Days ▼ 3.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
41.02%
12-Months-Change
Fundamentals
Return on Equity
15.92%
Trailing 12-Months
Asset Growth
3.77%
Trailing 12-Months
Company Description
Royalty Pharma PLC
Royalty Pharma (RPRX) is a leading buyer of biopharmaceutical royalties and a significant player in the pharmaceutical and biotechnology sectors. The company acquires existing royalty interests in various drug products, providing capital to innovators and stakeholders in the healthcare industry. By focusing on a diversified portfolio of royalty interests, Royalty Pharma supports the development of groundbreaking therapies while generating substantial returns.
RPRX Company Deck
RPRX Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a largely positive outlook with strong financial performance, strategic partnerships, and positive clinical developments. However, challenges such as the Vertex royalty dispute and operating cost issues were noted.View all RPRX earnings summariesRPRX Revenue Breakdown
93.34% Income from financial royalty assets
6.62% Other royalty income
0.04% Revenue from intangible royalty assets
RPRX Stock 12 Month Forecast
Average Price Target
$43.33
▲(18.71% Upside)
Technical Analysis
Ownership Overview
1.85% Insiders
21.37% Mutual Funds
23.72% Other Institutional Investors
36.55% Public Companies and
Individual Investors